Casper Pharma receives EIR from USFDA for its PAI
The inspection concluded with no observation (FDA-483) issued.
The inspection concluded with no observation (FDA-483) issued.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Subscribe To Our Newsletter & Stay Updated